Challenges of liver cancer: Future emerging tools in imaging and urinary biomarkers

World Journal of Hepatology

Volumn 7, Issue 26, 2015, Pages 2664-2675

  Trovato, Francesca M ^a   Tognarelli, Joshua M ^b   Crossey, Mary M E ^b   Catalano, Daniela ^a   Taylor Robinson, Simon D ^b   Trovato, Guglielmo M ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Fibrosis; Liver cancer; Ultrasound; Urinary biomarkers; Virus hepatitis

Indexed keywords

EID: 84962788291     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i26.2664     Document Type: Review

References (71)

1. Bodzin AS, Busuttil RW. Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol 2015; 7: 1157-1167 [PMID: 26019732 DOI: 10.4254/wjh.v7.i9.1157]
2. Trovato GM. Sustainable medical research by effective and comprehensive medical skills: overcoming the frontiers by predictive, preventive and personalized medicine. EPMA J 2014; 5: 14 [PMID: 25250099 DOI: 10.1186/1878-5085-5-14]
3. Pagni F, Bono F, Di Bella C, Faravelli A, Cappellini A. Virtual surgical pathology in underdeveloped countries: The Zambia Project. Arch Pathol Lab Med 2011; 135: 215-219 [PMID: 21284441 DOI: 10.1043/1543-2165-135.2.215]
4. Chen J, Jiao Y, Lu C, Zhou J, Zhang Z, Zhou C. A nationwide telepathology consultation and quality control program in China: implementation and result analysis. Diagn Pathol 2014; 9 Suppl 1: S2 [PMID: 25565398 DOI: 10.1186/1746-1596-9-S1-S2]
5. Hetzmann Z, Mostafa MG, Dalquen P. Computational Pathology and Telepathology: SY05-1 telecytology only an advantage for countries with underserved setting? Pathology 2014; 46 Suppl 2: S7
6. Ayad E, Sicurello F. Telepathology in emerging countries pilot project between Italy and Egypt. Diagn Pathol 2008; 3 Suppl 1: S2 [PMID: 18673508 DOI: 10.1186/1746-1596-3-S1-S2]
7. Chetwood JD, Ladep NG, Taylor-Robinson SD. Research partnerships between high and low-income countries: are international partnerships always a good thing? BMC Med Ethics 2015; 16: 36 [PMID: 26017015 DOI: 10.1186/s12910-015-0030-z]
8. Simonetti RG, Cammà C, Fiorello F, Politi F, D'Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991; 36: 962-972 [PMID: 1649041]
9. Catalano D, Trovato GM, Martines GF, Randazzo M, Tonzuso A. Bright liver, body composition and insulin resistance changes with nutritional intervention: a follow-up study. Liver Int 2008; 28: 1280-1287 [PMID: 18435716 DOI: 10.1111/j.1478-3231.2008.01742.x]
10. Trovato FM, Catalano D, Martines GF, Pace P, Trovato GM. Mediterranean diet and non-alcoholic fatty liver disease: the need of extended and comprehensive interventions. Clin Nutr 2015; 34: 86-88 [PMID: 24529325 DOI: 10.1016/j.clnu.2014.01.018]
11. Trovato FM, Catalano D, Garozzo A, Martines GF, Pirri C, Trovato GM. ADV36 adipogenic adenovirus in human liver disease. World J Gastroenterol 2014; 20: 14706-14716 [PMID: 25356033 DOI: 10.3748/wjg.v20.i40.14706]
12. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997; 350: 1142-1143 [PMID: 9343506]
13. Taylor-Robinson SD, Thomas HC, Arora S, Hargreaves S. Increased mortality from liver cancer in England and Wales is not related to hepatitis C. BMJ 1999; 319: 640 [PMID: 10473489 DOI: 10.1136/bmj.319.7210.640]
14. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366: 1303-1314 [PMID: 16214602]
15. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012; 61: 1657-1669 [PMID: 22895392 DOI: 10.1136/gutjnl-2011-301748]
16. Hsu CS, Chao YC, Lin HH, Chen DS, Kao JH. Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma. Sci Rep 2015; 5: 9954 [PMID: 25963067 DOI: 10.1038/srep09954]
17. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231 [PMID: 11961152]
18. Neuberger J, Grant A, Day CP, Saxseeena S. Guidelines on the use of liver biopsy in clinical practice. BSG Guidelines in Gastroenterology, 2004: 1-15
19. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-1457 [PMID: 14647056]
20. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008; 134: 1670-1681 [PMID: 18471546 DOI: 10.1053/j.gastro.2008.03.001]
21. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-974 [PMID: 18395077 DOI: 10.1053/j.gastro.2008.01.034]
22. Lim AK, Taylor-Robinson SD, Patel N, Eckersley RJ, Goldin RD, Hamilton G, Foster GR, Thomas HC, Cosgrove DO, Blomley MJ. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005; 54: 128-133 [PMID: 15591518]
23. Talwalkar JA, Yin M, Fidler JL, Sanderson SO, Kamath PS, Ehman RL. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 2008; 47: 332-342 [PMID: 18161879]
24. Lewin M, Poujol-Robert A, Boëlle PY, Wendum D, Lasnier E, Viallon M, Guéchot J, Hoeffel C, Arrivé L, Tubiana JM, Poupon R. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 2007; 46: 658-665 [PMID: 17663420]
25. Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ, Fidler JL, Ehman RL. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007; 5: 1207-1213.e2 [PMID: 17916548]
26. Lim AK, Patel N, Hamilton G, Hajnal JV, Goldin RD, Taylor-Robinson SD. The relationship of in vivo 31P MR spectroscopy to histology in chronic hepatitis C. Hepatology 2003; 37: 788-794 [PMID: 12668971]
27. Thomas EL, Hamilton G, Patel N, O'Dwyer R, Doré CJ, Goldin RD, Bell JD, Taylor-Robinson SD. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005; 54: 122-127 [PMID: 15591516]
28. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699 [PMID: 7560864]
29. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237-264 [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006]
30. RansohoffDF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978; 299: 926-930 [PMID: 692598]
31. Kirstein MM, Vogel A. The pathogenesis of hepatocellular carcinoma. Dig Dis 2014; 32: 545-553 [PMID: 25034287 DOI: 10.1159/000360499]
32. Koh C, Zhao X, Samala N, Sakiani S, Liang TJ, Talwalkar JA. AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations. Hepatology 2013; 58: 2142-2152 [PMID: 23775835 DOI: 10.1002/hep.26578]
33. Leoni S, Piscaglia F, Serio I, Terzi E, Pettinari I, Croci L, Marinelli S, Benevento F, Golfieri R, Bolondi L. Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. Dig Liver Dis 2014; 46: 549-555 [PMID: 24630947 DOI: 10.1016/j.dld.2014.02.012]
34. Cucchetti A, Trevisani F, Pecorelli A, Erroi V, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Giannini EG, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Baroni GS, Virdone R, Bernardi M, Pinna AD. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. J Hepatol 2014; 61: 333-341 [PMID: 24717522 DOI: 10.1016/j.jhep.2014.03.037]
35. Del Poggio P, Olmi S, Ciccarese F, Di Marco M, Rapaccini GL, Benvegnù L, Borzio F, Farinati F, Zoli M, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014; 12: 1927-33.e2 [PMID: 24582947 DOI: 10.1016/j.cgh.2014.02.025]
36. Sherman M, Bruix J, Porayko M, Tran T. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology 2012; 56: 793-796 [PMID: 22689409 DOI: 10.1002/hep.25869]
37. Taylor-Robinson SD, Wong J, Crossey MM, Khan SA. Evidence is weak to support hepatocellular carcinoma screening in chronic liver disease. Evid Based Med 2015; 20: 59 [PMID: 25694341 DOI: 10.1136/ebmed-2014-110107]
38. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Cammà C, Colombo M. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011; 54: 2055-2063 [PMID: 21898496 DOI: 10.1002/hep.24644]
39. Abou-Alfa GK. Sorafenib use in hepatocellular carcinoma: more questions than answers. Hepatology 2014; 60: 15-18 [PMID: 24493250 DOI: 10.1002/hep.27044]
40. Perdomo AB, Ciccosanti F, Iacono OL, Angeletti C, Corazzari M, Daniele N, Testa A, Pisa R, Ippolito G, Antonucci G, Fimia GM, Piacentini M. Liver protein profiling in chronic hepatitis C: identification of potential predictive markers for interferon therapy outcome. J Proteome Res 2012; 11: 717-727 [PMID: 22098443 DOI: 10.1021/pr2006445]
41. Simerville JA, Maxted WC, Pahira JJ. Urinalysis: a comprehensive review. Am Fam Physician 2005; 71: 1153-1162 [PMID: 15791892]
42. Subramonian K, MacDonald H, Vijapurapu R, Yadav S. Urine Dipstick Tests. Student BMJ 2009; 17: b260 [DOI: 10.1136/sbmj.b260]
43. ShariffMI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol 2009; 3: 353-367 [PMID: 19673623 DOI: 10.1586/egh.09.35]
44. Nicholson JK, Lindon JC. Systems biology: Metabonomics. Nature 2008; 455: 1054-1056 [PMID: 18948945 DOI: 10.1038/4551054a]
45. Ho Y, Lin HJ. Patterns of excretion of methylated purines in hepatocellular carcinoma. Cancer Res 1974; 34: 986-990 [PMID: 4363066]
46. Criss WE, Murad F. Urinary excretion of cyclic guanosine 3': 5'-monophosphate and cyclic adenosine 3': 5'-monophosphate in rats bearing transplantable liver and kidney tumors. Cancer Res 1976; 36: 1714-1716 [PMID: 178429]
47. Dusheiko GM, Levin J, Kew MC. Cyclic nucleotides in biological fluids in hepatocellular carcinoma. Cancer 1981; 47: 113-118 [PMID: 6257369]
48. Tamura S, Amuro Y, Nakano T, Fujii J, Moriwaki Y, Yamamoto T, Hada T, Higashino K. Urinary excretion of pseudouridine in patients with hepatocellular carcinoma. Cancer 1986; 57: 1571-1575 [PMID: 2418945]
49. Jeng LB, Lo WY, Hsu WY, Lin WD, Lin CT, Lai CC, Tsai FJ. Analysis of urinary nucleosides as helper tumor markers in hepatocellular carcinoma diagnosis. Rapid Commun Mass Spectrom 2009; 23: 1543-1549 [PMID: 19399767 DOI: 10.1002/rcm.4034]
50. Katoh M, Inagaki H, Kurosawa-Ohsawa K, Katsuura M, Tanaka S. Detection of transforming growth factor alpha in human urine and plasma. Biochem Biophys Res Commun 1990; 167: 1065-1072 [PMID: 2157422]
51. Chuang LY, Tsai JH, Yeh YC, Chang CC, Yeh HW, Guh JY, Tsai JF. Epidermal growth factor-related transforming growth factors in the urine of patients with hepatocellular carcinoma. Hepatology 1991; 13: 1112-1116 [PMID: 1646759]
52. Tsai JF, Jeng JE, Chuang LY, Yang ML, Ho MS, Chang WY, Hsieh MY, Lin ZY, Tsai JH. Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma. Br J Cancer 1997; 75: 1460-1466 [PMID: 9166938]
53. Kawasaki H, Watanabe H, Yamada S, Watanabe K, Suyama A. Prognostic significance of urinary neopterin levels in patients with hepatocellular carcinoma. Tohoku J Exp Med 1988; 155: 311-318 [PMID: 2852855]
54. Daito K, Suou T, Kawasaki H. Clinical significance of serum and urinary neopterin levels in patients with various liver diseases. Am J Gastroenterol 1992; 87: 471-476 [PMID: 1313206]
55. Sucher R, Schroecksnadel K, Weiss G, Margreiter R, Fuchs D, Brandacher G. Neopterin, a prognostic marker in human malignancies. Cancer Lett 2010; 287: 13-22 [PMID: 19500901 DOI: 10.1016/j.canlet.2009.05.008]
56. Motyl T, Traczyk Z, Holska W, Daniewska-Michalska D, Ciesluk S, Kukulska W, Kaluzny Z, Podgurniak M. Comparison of urinary neopterin and pseudouridine in patients with malignant proliferative diseases. Eur J Clin Chem Clin Biochem 1993; 31: 205-209 [PMID: 8318566]
57. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, Cheng D, Jewell K, Arndt D, Sawhney S, Fung C, Nikolai L, Lewis M, Coutouly MA, Forsythe I, Tang P, Shrivastava S, Jeroncic K, Stothard P, Amegbey G, Block D, Hau DD, Wagner J, Miniaci J, Clements M, Gebremedhin M, Guo N, Zhang Y, Duggan GE, Macinnis GD, Weljie AM, Dowlatabadi R, Bamforth F, Clive D, Greiner R, Li L, Marrie T, Sykes BD, Vogel HJ, Querengesser L. HMDB: the Human Metabolome Database. Nucleic Acids Res 2007; 35: D521-D526 [PMID: 17202168]
58. Antoniello S, Auletta M, Magri P, Pardo F. Urinary excretion of free and acetylated polyamines in hepatocellular carcinoma. Int J Biol Markers 1998; 13: 92-97 [PMID: 9803357]
59. Lin SD, Endo R, Kuroda H, Kondo K, Miura Y, Takikawa Y, Kato A, Suzuki K. Plasma and urine levels of urinary trypsin inhibitor in patients with chronic liver diseases and hepatocellular carcinoma. J Gastroenterol Hepatol 2004; 19: 327-332 [PMID: 14748881]
60. Kikuchi I, Uchinami H, Nanjo H, Hashimoto M, Nakajima A, Kume M, Mencin A, Yamamoto Y. Clinical and prognostic significance of urinary trypsin inhibitor in patients with hepatocellular carcinoma after hepatectomy. Ann Surg Oncol 2009; 16: 2805-2817 [PMID: 19636634 DOI: 10.1245/s10434-009-0622-2]
61. Wu H, Xue R, Dong L, Liu T, Deng C, Zeng H, Shen X. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta 2009; 648: 98-104 [PMID: 19616694 DOI: 10.1016/j.aca.2009.06.033]
62. ShariffMI, Ladep NG, Cox IJ, Williams HR, Okeke E, Malu A, Thillainayagam AV, Crossey MM, Khan SA, Thomas HC, Taylor-Robinson SD. Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. J Proteome Res 2010; 9: 1096-1103 [PMID: 19968328 DOI: 10.1021/pr901058t]
63. Ladep NG, Dona AC, Lewis MR, Crossey MM, Lemoine M, Okeke E, Shimakawa Y, Duguru M, Njai HF, Fye HK, Taal M, Chetwood J, Kasstan B, Khan SA, Garside DA, Wijeyesekera A, Thillainayagam AV, Banwat E, Thursz MR, Nicholson JK, Njie R, Holmes E, Taylor-Robinson SD. Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans. Hepatology 2014; 60: 1291-1301 [PMID: 24923488 DOI: 10.1002/hep.27264]
64. ShariffMI, Gomaa AI, Cox IJ, Patel M, Williams HR, Crossey MM, Thillainayagam AV, Thomas HC, Waked I, Khan SA, Taylor-Robinson SD. Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. J Proteome Res 2011; 10: 1828-1836 [PMID: 21275434 DOI: 10.1021/pr101096f]
65. Songserm N, Promthet S, Sithithaworn P, Pientong C, Ekalaksananan T, Chopjitt P, Parkin DM. Risk factors for cholangiocarcinoma in high-risk area of Thailand: role of lifestyle, diet and methylenetetrahydrofolate reductase polymorphisms. Cancer Epidemiol 2012; 36: e89-e94 [PMID: 22189445 DOI: 10.1016/j.canep.2011.11.007]
66. Trovato FM, Catalano D, Ragusa A, Martines GF, Pirri C, Buccheri MA, Di Nora C, Trovato GM. Relationship of MTHFR gene polymorphisms with renal and cardiac disease. World J Nephrol 2015; 4: 127-137 [PMID: 25664255 DOI: 10.5527/wjn.v4.i1.127]
67. Catalano D, Trovato GM, Ragusa A, Martines GF, Tonzuso A, Pirri C, Buccheri MA, Trovato FM. Non-alcoholic fatty liver disease (NAFLD) and MTHFR 1298A > C gene polymorphism. Eur Rev Med Pharmacol Sci 2014; 18: 151-159 [PMID: 24488901]
68. Wadsworth CA, Dixon PH, Wong JH, Chapman MH, McKay SC, Sharif A, Spalding DR, Pereira SP, Thomas HC, Taylor-Robinson SD, Whittaker J, Williamson C, Khan SA. Genetic factors in the pathogenesis of cholangiocarcinoma. Dig Dis 2011; 29: 93-97 [PMID: 21691113 DOI: 10.1159/000324688]
69. Khan SA, Emadossadaty S, Ladep NG, Thomas HC, Elliott P, Taylor-Robinson SD, Toledano MB. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol 2012; 56: 848-854 [PMID: 22173164 DOI: 10.1016/j.jhep.2011.11.015]
70. Ladep NG, Khan SA, Crossey MM, Thillainayagam AV, Taylor-Robinson SD, Toledano MB. Incidence and mortality of primary liver cancer in England and Wales: changing patterns and ethnic variations. World J Gastroenterol 2014; 20: 1544-1553 [PMID: 24587630 DOI: 10.3748/wjg.v20.i6.1544]
71. Trovato FM, Catalano D, Musumeci G, Trovato GM. 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics. EPMA J 2014; 5: 21 [PMID: 25937854 DOI: 10.1186/1878-5085-5-21]